Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 31, 2026
Anheuser-Busch InBev (BUD) Posts Solid Q2 Results but China Weakness Sends Shares Down 2%

Anheuser-Busch InBev (BUD) Posts Solid Q2 Results but China Weakness Sends Shares Down 2%

Key Takeaways

  • Revenue and EPS beat estimates: Anheuser-Busch InBev reported Q2 2026 revenue of $16.66 billion (up 5.6% organically) and underlying earnings per share of $1.21, topping consensus estimates of $16.39 billion and $1.12 respectively.
  • Beer volumes returned to growth: Global beer volumes rose 1.1% in the quarter, marking a continuation of positive momentum, while total volumes increased 0.9% year over year.
  • Megabrands and Beyond Beer drove outperformance: Combined revenue from megabrands grew 6.2%, led by Corona (up 17% outside its home market), while Beyond Beer revenue surged 44% and no-alcohol beer climbed 27%.
  • China remained a significant drag: China volumes fell 9.7% in the quarter, driven by adverse weather and persistent weakness in on-premise channels, weighing on investor sentiment.
  • Stock declined despite the beat: BUD shares fell roughly 2% on July 30 as the China headwinds overshadowed an otherwise strong set of global results.
  • Full-year guidance reaffirmed: Management reiterated its fiscal 2026 EBITDA (earnings before interest, taxes, depreciation, and amortization) growth outlook of 4% to 8%.

Why These Earnings Matter

Anheuser-Busch InBev, the world's largest brewer and owner of iconic brands such as Budweiser, Corona, Stella Artois, and Michelob Ultra, delivered its second-quarter 2026 results against a backdrop of uneven global consumer demand. This earnings report carried heightened significance for several reasons: it was the first full quarter to capture the demand uplift from the FIFA World Cup, it provided a reading on whether recent volume stabilization could translate into sustained growth, and it offered a critical update on the company's premiumization and digital transformation strategy. Coming off a strong Q1 in which BUD also exceeded expectations, investors closely watched whether the brewer could maintain momentum across its diverse geographic portfolio, particularly as macroeconomic headwinds persisted in key markets. The results ultimately confirmed the company's operational strength globally while exposing ongoing challenges in China. I also checked comparable names in the sector using Tickeron’s AI Screener to put the results in context.

The Quarter in Detail

For the second quarter ended June 30, 2026, AB InBev reported organic revenue growth of 5.6% to $16.66 billion, comfortably exceeding the analyst consensus estimate of approximately $16.34–$16.39 billion. On a reported basis, revenue increased 11.0%, benefiting from favorable currency translation effects. Revenue per hectoliter rose 4.2%, reflecting disciplined revenue management and a favorable product mix shift toward premium brands.

Underlying earnings per share (EPS) surged 23.4% year over year to $1.21, beating consensus estimates of $1.12 by $0.09. Underlying profit attributable to equity holders reached $2.39 billion, up from $1.95 billion in the same quarter last year. On a reported basis, profit attributable to equity holders jumped to $3.75 billion from $1.68 billion in the prior-year period, supported by non-underlying items.

Normalized EBITDA grew 5.8% to $5.94 billion, with the EBITDA margin expanding 4 basis points to 35.6%, even as the company increased sales and marketing investments. Free cash flow for the first half of 2026 improved dramatically, rising by $2.53 billion to $3.88 billion, reflecting stronger operating profit and improved working capital management. The company's net debt-to-normalized EBITDA ratio improved to 2.86x from 3.27x a year earlier.

Beer volumes returned to growth at 1.1%, while total volumes — including non-beer products — rose 0.9%. Performance was broad-based across four of the company's five geographic zones, with standout results in Middle Americas and South America. The North America segment posted a 2.7% revenue increase, driven by Michelob Ultra, Busch Light, and the Beyond Beer portfolio. However, the Asia Pacific region underperformed, with China volumes declining 9.7% and revenue falling 8.6%, as weak weather and subdued on-premise traffic continued to pressure the business.

Market Reaction

Despite a headline beat on both revenue and earnings, BUD shares declined roughly 2% in premarket and intraday trading on July 30, reflecting a clear tension between the company's global strength and the persistent weakness in its Chinese operations. The stock, which had climbed approximately 33.7% year-to-date and was trading near its 52-week high of $85.56 heading into the report, faced selling pressure as investors digested the magnitude of the China slowdown. AB InBev's Asia Pacific subsidiary, Budweiser APAC, reported that China volumes fell 9.7% and revenue dropped 8.6% in the second quarter, with management acknowledging that more work is needed to stabilize that market. This overshadowed otherwise solid results from Latin America, Europe, and North America. The market's reaction underscores how elevated expectations and the concentrated nature of China's headwinds can weigh on sentiment, even when the broader business is performing well. From what I see, the premiumization trends remain a bright spot worth monitoring closely.

Forward Outlook and What I’m Watching

Management reaffirmed its full-year 2026 EBITDA growth guidance of 4% to 8%, signaling confidence that the underlying business momentum can absorb near-term pressures. The company expects growth to be more evenly balanced between the first and second halves of the year, supported in part by transactional foreign exchange effects that are projected to turn from headwinds into tailwinds, particularly in Mexico and Brazil.

Several factors will be critical for investors to monitor in the months ahead. First, the trajectory of the Chinese market remains the most significant wild card. Management has indicated that the on-premise channel has shown no meaningful improvement through July, and channel inventory levels may continue to decline modestly in the second half. Any stabilization or recovery in China would be a powerful catalyst for sentiment, while further deterioration could continue to weigh on the stock.

Second, the company's premiumization strategy continues to deliver results, with megabrands, no-alcohol beer, and Beyond Beer all posting double-digit growth. The sustained double-digit expansion of Corona, Stella Artois, and Michelob Ultra outside their home markets underscores the global appeal of AB InBev's brand portfolio. Third, the digital ecosystem — particularly the BEES B2B (business-to-business) marketplace, which saw gross merchandise value rise 50% to $1.2 billion — represents a growing source of efficiency and revenue diversification that deserves continued attention.

On the cost side, management flagged potential pressure from unhedged energy and logistics costs in the second half, though disciplined revenue management and premiumization are expected to provide partial offsets. The company's $6 billion share buyback program, of which $1.9 billion had been completed as of July 24, also provides a structural support element for the stock. Lastly, capital expenditures are projected to remain within the $3.5 billion to $4 billion range for the full year, while the normalized effective tax rate is expected to land between 26% and 28%.

Enhancing Research with Tickeron Tools

In my own process, I often turn to Tickeron’s AI Screener when evaluating earnings reports like this one. It helps quickly filter peers by fundamentals, volume trends, and technical signals so I can see how BUD stacks up without spending hours on manual screens. The tool surfaces ideas that align with specific criteria, which I find useful during busy earnings seasons.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BUD

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


BUD in downward trend: 10-day moving average crossed below 50-day moving average on August 18, 2026

The 10-day moving average for BUD crossed bearishly below the 50-day moving average on August 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BUD as a result. In 36 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 46%.

The Moving Average Convergence Divergence Histogram (MACD) for BUD turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 24 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 55%.

BUD moved below its 50-day moving average on August 11, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BUD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +1.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where BUD advanced for three days, in 186 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

BUD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 119 of 260 cases where BUD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 46%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating for company is 31 (best 1 - 100 worst), which means the company is slightly undervalued. The valuation of the company is based on a proprietary formula which takes into account a set of fundamentals and gives us an estimate of the price per share for the company. We then compare this estimate with the current price per share. As a result, this company is rated as undervalued in the industry. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.647) is normal, around the industry mean (2.083). P/E Ratio (16.860) is within average values for comparable stocks, (16.825). Projected Growth (PEG Ratio) (1.608) is also within normal values, averaging (2.419). BUD has a moderately low Dividend Yield (0.017) as compared to the industry average of (0.038). BUD's P/S Ratio (2.511) is slightly higher than the industry average of (1.525).

The Tickeron PE Growth Rating for this company is 39 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 49 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. BUD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Anheuser-Busch INBEV SA/NV (NYSE:BUD), Constellation Brands (NYSE:STZ), Molson Coors Beverage Company (NYSE:TAP).

Industry description

The meat, fish, and dairy food industry processes livestock, fish and milk products for consumer consumption. Some companies also process dairy byproducts. Tyson Foods, Inc., Hormel Foods Corporation and Pilgrims Pride Corp. are some of the biggest producers in this industry. Many of these companies are recipients of American farm subsidies. On the other hand, new-age food innovation like plant-based meat substitutes (which are designed to simulate chicken, beef, and pork sausage) could potentially augur disruptions and/or create new competition in this space.

Market Cap

The average market capitalization across the Food: Meat/Fish/Dairy Industry is 38.98B. The market cap for tickers in the group ranges from 317.04K to 154.57B. BUDFF holds the highest valuation in this group at 154.57B. The lowest valued company is ENHD at 317.04K.

High and low price notable news

The average weekly price growth across all stocks in the Food: Meat/Fish/Dairy Industry was -2%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was -3%. SAM experienced the highest price growth at 2%, while STZ experienced the biggest fall at -4%.

Volume

The average weekly volume growth across all stocks in the Food: Meat/Fish/Dairy Industry was 53%. For the same stocks of the Industry, the average monthly volume growth was 83% and the average quarterly volume growth was 19%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 24
P/E Growth Rating: 58
Price Growth Rating: 56
SMR Rating: 60
Profit Risk Rating: 77
Seasonality Score: -52 (-100 ... +100)
View a ticker or compare two or three
BUD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a holding company whose subsidiaries manufactures and distributes alcoholic and non-alcoholic beverages

Industry FoodMeatFishDairy

Profile
Details
Industry
Beverages Alcoholic
Address
Brouwerijplein 1
Phone
+32 16276888
Employees
143000
Web
https://www.ab-inbev.com
Interact to see
Advertisement
HIMS shares surged approximately +43.85% in premarket trading on Monday, March 9, 2026, rising from a prior close of $15.74 to around $22.80. Primary catalyst: Novo Nordisk officially ended its patent infringement lawsuit against Hims & Hers and announced a landmark partnership to distribute branded Wegovy through the Hims platform at $599/month.
XENE shares surged approximately +45.93% in premarket trading on March 9, 2026, one of the largest single-session moves in the company's history. The primary catalyst: Xenon announced positive topline Phase 3 X-TOLE2 results for its lead drug candidate azetukalner in focal onset seizures (FOS), meeting the primary endpoint with overwhelming statistical significance.
Shares of OLMA dropped approximately 41% in Monday's session, one of the steepest single-day declines in the company's history. The primary catalyst was Roche's Phase 3 persevERA trial failure — a late-stage study of giredestrant, a closely competing selective estrogen receptor degrader (SERD), which missed its primary endpoint of statistically significant improvement in progression-free survival.
RLMD shares surged approximately +40% at the open on March 9, 2026, rising from a prior close of $4.45 to approximately $6.23, driven by a major clinical trial readout. The primary catalyst was the announcement of 12-month interim data from the Phase 2 trial of NDV-01, Relmada's lead oncology candidate, in patients with high-risk non-muscle invasive bladder cancer (NMIBC) — results that significantly exceeded historical benchmarks.
CRCL surged +8.66% on Monday, March 9, 2026, rising from a prior close of $101.94 to trade at $110.77 intraday. The primary catalyst is a landmark stablecoin milestone: Circle's USDC overtook Tether as the dominant stablecoin by transfer volume, accounting for approximately 70% of all stablecoin transfer activity as total stablecoin transfers hit $1.8 trillion in February.
Carnival Corporation (CCL) shares fell approximately -7.60% in Monday's session, dropping from a Friday close of $25.79 to around $23.83. The primary catalyst is a broad market sell-off driven by intensifying recession fears, with the S&P 500 and consumer discretionary names bearing the brunt of the pressure.
Shares of Bloom Energy (BE) are surging approximately +10.30% in Monday's session, rebounding sharply from a steep -15.50% selloff on Friday, March 6, 2026. Friday's decline was triggered by an Oracle-OpenAI data center project update that spooked energy infrastructure investors; Monday's move reflects aggressive dip-buying and a sentiment reset.
IGV has rallied about 8–9% in the last 6 trading days, while SOXX has dropped about 8%, giving software a +16.6 percentage‑point edge—the largest 6‑day software‑over‑semi outperformance ever.[barchart]​ This comes right after software lagged semis by almost −15 percentage points into late January, the widest gap since 2008, and as hedge‑fund short exposure to U.S. software and services hit a record ~3.8% of market cap.
Crude’s explosive war‑driven spike faded on March 9 because the market suddenly started to price less extreme, shorter‑lived supply risk and more policy intervention, not a multi‑month shortage. WTI, which had briefly traded above 115–120 dollars on Iran‑war headlines and Strait of Hormuz fears, slid back toward the high‑80s as traders digested G7 reserve‑release talk, Trump’s comments about a “brief” war, and the reality that prices had run far ahead of fundamentals.
Shares of ARQ plunged approximately 27.50% in premarket trading on March 10, 2026, from a prior close of $3.20 to roughly $2.32. The primary catalyst was a deeply disappointing Q4 2025 earnings report, which revealed a net loss of $50.0 million for the quarter versus a net loss of $1.3 million in Q4 2024.
RAIL shares fell approximately 15% in premarket trading on March 10, 2026, following a steep after-hours reaction to disappointing Q4 2025 earnings results released after the close on March 9. The primary catalyst was a significant revenue miss: Q4 revenue came in at $125.6 million, well below consensus estimates near $144–$160 million, representing an 8.8% year-over-year decline.
ZVRA shares surged approximately +17.86% on March 10, 2026, driven by a blockbuster Q4 and full-year 2025 earnings report released before the market open. Primary catalyst: Q4 2025 EPS of $0.19 crushed the consensus estimate of $0.05 — a 280% beat — while revenue of $34.1 million exceeded forecasts by 21.57%.
LITE surged +14.73% on Monday, March 9, 2026, closing at $640.69 versus a prior close of $558.44 on March 6. The primary catalyst was the landmark $2 billion strategic investment by NVIDIA announced March 2, with the market continuing to price in its full implications following a brief post-announcement pullback.
Shares of BNTX fell approximately 22% on Tuesday, March 10, 2026, following a dual shock of disappointing full-year guidance and a surprise leadership upheaval. The primary catalyst was BioNTech's Q4 2025 earnings report, which included a 2026 revenue outlook of €2.0–€2.3 billion — well below analyst consensus and signaling continued pressure from declining COVID-19 vaccine demand.
CNC shares fell approximately 10% during Tuesday's session, extending a prolonged selloff in the managed care sector. The primary catalyst is intensifying investor concern over federal Medicaid and ACA funding cuts tied to the "One Big Beautiful Bill Act" (OBBBA), which threatens to shrink the government-sponsored insurance pools that Centene depends on for the majority of its revenue.
Technology recently peaked near 35% of the S&P 500 and has slipped over the last year, while Energy plus Materials remain near historically low combined weight at roughly 6%, which suggests the gap is still unusually wide.
Average daily equity purchases by retail investors on S&P 500 down days in 2026 are at the highest level on record, running about 100% above the peak intensity seen during the 2021 meme‑stock boom.
Over the past two weeks, PLTR has climbed from roughly the high‑130s to the mid‑150s, a gain of about 12–14%, with a series of strong up days between March 2 and March 6.
AVAV shares dropped approximately 10% in premarket trading on March 11, 2026, following a disappointing Q3 fiscal 2026 earnings report released after the prior session's close. Q3 revenue of $408.0 million came in far below analyst consensus of approximately $475–$488 million, representing a massive top-line miss.
KOS shares are down approximately 20% in premarket trading on March 11, 2026, having shed roughly 20.31% across the last two sessions (Tuesday close and premarket Wednesday). The primary catalyst is Kosmos Energy's announcement of a massive $185.25 million public equity offering priced at $1.90 per share — a steep discount to recent trading levels.